Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:39 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 1,207 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Low Dose Drug A Clear all

Conditions: Myelodysplastic Syndrome
Interventions: Clofarabine; Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Contraception
Interventions: AG200-15 (cycles 1-13), Lessina crossover to AG200-15; Drug
Lead sponsor: Agile Therapeutics; Industry
Eligibility: 17 Years to 40 Years · Female only
Enrollment: 1,504 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 80
States / cities: Huntsville, Alabama • Mobile, Alabama • Chandler, Arizona + 77 more

Conditions: Depression
Interventions: SSRI + LD, SSRI + PHD; Behavioral
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Cardiovascular Disease
Interventions: Antioxidant cocktail, Biopsy, Placebo, NMD; 0.4mg sub-lingual nitroglycerin spray; Dietary Supplement · Other · Drug
Lead sponsor: Augusta University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2027
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Hemophilia A
Interventions: rFVIIIFc; Biological
Lead sponsor: Bioverativ, a Sanofi company; Industry
Eligibility: Up to 5 Years · Male only
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 20
States / cities: Little Rock, Arkansas • Duarte, California • Sacramento, California + 16 more

Conditions: Diabetic Retinopathy, Diabetes Complications
Interventions: Laser Treatment, PF-04523655 high, PF-04523655 middle, PF-04523655 low; Procedure · Drug
Lead sponsor: Quark Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 26
States / cities: Mesa, Arizona • Meza, Arizona • Peoria, Arizona + 20 more

Conditions: Obstructive Sleep Apnea
Interventions: IHL-42X Low Dose, IHL-42X High Dose, Placebo, IHL-42X (Optimal Dose), Dronabinol, Acetazolamide; Drug
Lead sponsor: Incannex Healthcare Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 20
States / cities: Chula Vista, California • Long Beach, California • Upland, California + 16 more

Conditions: Cystic Fibrosis, Iron Deficiencies, Iron Deficiency Diseases
Interventions: IV Repletion, PO Repletion; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 8
States / cities: Denver, Colorado • Indianapolis, Indiana • Kansas City, Kansas + 5 more

Conditions: Metastatic or Locally Advanced Unresectable Solid Tumors
Interventions: M1774, Niraparib; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 5
States / cities: Boston, Massachusetts • Austin, Texas • Dallas, Texas + 1 more

Conditions: Attention-Deficit Hyperactivity Disorder (ADHD)
Interventions: PDC-1421 Capsule, Placebo; Drug
Lead sponsor: BioLite, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Osteoporosis
Interventions: Teriparatide, Risedronate, Placebo, Calcium, Vitamin D; Drug · Dietary Supplement
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 50 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 6
States / cities: Fort Lauderdale, Florida • New Port Richey, Florida • Orlando, Florida + 3 more

Conditions: Bipolar Disorder
Interventions: Metformin, healthy lifestyle intervention (LIFE); Drug · Behavioral
Lead sponsor: Melissa Delbello; Other
Eligibility: 8 Years to 19 Years
Enrollment: 1,565 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 29
States / cities: Covington, Kentucky • Neptune City, New Jersey • Amityville, New York + 13 more

Conditions: COVID-19
Interventions: REGN10933+REGN10987 combination therapy, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 2,252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 96
States / cities: Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 70 more

Conditions: Advanced Cancer, Ovarian Cancer, Lung Cancer, Colon Cancer, Plasma Cell Neoplasm, Multiple Myeloma, HNSCC, Microsatellite Stable Colorectal Carcinoma, MSS-CRC
Interventions: Dose escalation: COM902 monotherapy., Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE), Cohort expansion: COM902 (RDFE) monotherapy., Cohort expansion: COM902 in combination with COM701 (both at the RDFE)., Cohort expansion: Triplet combination of COM902 + COM701 + Pembrolizumab.; Drug · Combination Product
Lead sponsor: Compugen Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 9
States / cities: Sarasota, Florida • Boston, Massachusetts • Grand Rapids, Michigan + 6 more

Conditions: Breast Cancer, Solid Tumors, Adult
Interventions: STX-478, Fulvestrant, Ribociclib, Palbociclib, Letrozole, Anastrozole, Exemestane, Tamoxifen, Abemaciclib, Imlunestrant, Metformin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 880 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 28
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 22 more

Conditions: Parkinson Disease
Interventions: CVT-301 (Dose Level 1), CVT-301 (Dose Level 2), Sinemet®; Drug
Lead sponsor: Acorda Therapeutics; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Traumatic Brain Injury, Posttraumatic Epilepsy
Interventions: Allopregnanolone injection, Placebo injection; Drug
Lead sponsor: Michael A. Rogawski, MD, PhD; Other
Eligibility: 16 Years to 65 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Statin Adverse Reaction
Interventions: Low-dose colchicine at 0.5mg daily, Placebo; Drug · Other
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: H7N9 Influenza
Interventions: H7N9c low dose with adjuvant, H7N9c medium dose with adjuvant, H7N9c high dose with adjuvant, H7N9c high dose without adjuvant; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 402 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 6
States / cities: San Diego, California • Melbourne, Florida • Peoria, Illinois + 2 more

Conditions: Burns
Interventions: Ketamine, Sodium chloride; Drug
Lead sponsor: Loyola University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Gastrointestinal Neoplasms, Genitourinary Cancer, Thoracic Cancer, Sarcoma, Melanoma
Interventions: ICI Therapy; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Dravet Syndrome (DS)
Interventions: Soticlestat, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 2 Years to 21 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 10
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 7 more

Conditions: Cancer
Interventions: IPTLD and nutrition therapy; Other
Lead sponsor: Best Answer for Cancer Foundation; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Breast Cancer
Interventions: Molecular Breast Imaging, Conventional Mammography, Technetium (99mTc) sestamibi; Device · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 25 Years and older · Female only
Enrollment: 969 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

Safety and Tolerability of Oral Clofarabine in Intermediate to High Risk Myelodysplastic Patients

Study to Evaluate the Contraceptive Efficacy/Safety of a Low Dose EE/LNG Transdermal Contraceptive Delivery System

Adding Exercise to Antidepressant Medication Treatment for Depression

Nitric Oxide Bioavailability and Early Life Stress (NO-Stress)

An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Previously Untreated Males With Severe Hemophilia A

Study Evaluating Efficacy and Safety of PF-04523655 Versus Laser in Subjects With Diabetic Macular Edema

RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA

Iron Repletion in Cystic Fibrosis

Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

PDC-1421 Treatment in Adult Patients With ADHD

A Study That Will Compare the Effect of Two Drugs on Participants With Low Bone Mass and a Recent Hip Fracture

Metformin for Overweight & OBese ChILdren and Adolescents With BDS Treated With SGAs

Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19

COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

A Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (Carbidopa-levodopa) Tablets

Allopregnanolone for the Treatment of Traumatic Brain Injury

Safety and Efficacy of LOw DOse COlchicine in Patients With STatin INTolerance: the LODOCO STINT Pilot Study

Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years

Intraoperative Low-dose Ketamine Infusion as the Main Analgesic in Burn Patients

Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study

A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome

A Quality of Life Study Using Insulin Potentiation Targeted LowDose (IPTLD) Chemotherapy and Nutrition Therapy in the Treatment of Cancer

Molecular Breast Imaging as a Screening Tool for Women With Dense Breasts